Physiologically Based Pharmacokinetic Modeling of Lurasidone, an Antipsychotic Drug: Impact of CYP3A4 Polymorphisms and Hepatic Impairment on Exposure and Dose Optimization.

Abstract excerpt

Lurasidone is an antipsychotic drug used to treat schizophrenia and bipolar depression, primarily metabolized by cytochrome P450 3A4 (CYP3A4). Its pharmacokinetics (PK) can vary depending on CYP3A4 genetic polymorphisms and liver function, often requiring clinical dose adjustments. However, there is a lack of systematic tools for quantitatively predicting such interindividual variability. This study aimed to...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Antipsychotic Agents
• Share to Computer Simulation